{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:38:01Z","timestamp":1794980281905,"version":"4.9.1"},"reference-count":137,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,25]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>For patients with immune thrombocytopenia (ITP), a critical bleed, such as intracranial hemorrhage or bleeding causing hemodynamic instability, requires urgent treatment to rapidly raise the platelet count and restore hemostasis. There is no standardized approach to this hematologic emergency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The McMaster ITP Emergency Management Guideline Group developed evidence-informed recommendations for the management of a critical bleed in adults and children with ITP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The guideline panel included 5 clinical experts in adult ITP, 3 clinical experts in pediatric ITP, 2 emergency department physicians, 1 emergency department nurse, 2 methodologists, and 4 patient partners. To inform recommendations, the guideline team conducted a multicenter retrospective cohort study and systematic reviews. The panel used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to rate the certainty in the evidence and GRADE evidence-to-decision framework to formulate recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Given the life-threatening nature or significant morbidity associated with the condition, despite low or very low certainty in the evidence, the panel made strong recommendations for the combined use of high-dose corticosteroids, high-dose IV immunoglobulin (IVIG), platelet transfusions, tranexamic acid, and thrombopoietin receptor agonists (TPO-RAs) for the treatment of adults or children with a critical ITP bleed. The panel made a conditional recommendation for urgent splenectomy when other treatments have failed and, due to the risk of thrombosis, a conditional recommendation against the use of recombinant factor VIIa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Motivated by the life-threatening nature of the condition, the panel made strong recommendations for the combined use of high-dose corticosteroids, high-dose IVIG, platelet transfusions, tranexamic acid, and TPO-RAs for the emergency management of adults and children with a critical ITP bleed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018818","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T19:39:27Z","timestamp":1770233967000},"page":"5558-5575","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Guideline on the emergency management of critical bleeding in patients with immune thrombocytopenia"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4361-0792","authenticated-orcid":false,"given":"Saifur R.","family":"Chowdhury","sequence":"first","affiliation":[{"name":"1Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada"},{"name":"2Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Sirotich","sequence":"additional","affiliation":[{"name":"1Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada"},{"name":"2Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2352-5718","authenticated-orcid":false,"given":"Gordon","family":"Guyatt","sequence":"additional","affiliation":[{"name":"2Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"},{"name":"3Department of Medicine, McMaster University, Hamilton, ON, Canada"},{"name":"4MAGIC Evidence Ecosystem Foundation, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5879-4179","authenticated-orcid":false,"given":"Dimpy","family":"Modi","sequence":"additional","affiliation":[{"name":"1Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada"},{"name":"3Department of Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3595-5697","authenticated-orcid":false,"given":"Adam","family":"Cuker","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"6Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5168-0243","authenticated-orcid":false,"given":"Vicky R.","family":"Breakey","sequence":"additional","affiliation":[{"name":"7Division of Pediatric Hematology\/Oncology, Department of Pediatrics, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-0449","authenticated-orcid":false,"given":"Rachael F.","family":"Grace","sequence":"additional","affiliation":[{"name":"8Dana-Farber\/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6053-689X","authenticated-orcid":false,"given":"Menaka","family":"Pai","sequence":"additional","affiliation":[{"name":"1Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada"},{"name":"3Department of Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5049-1176","authenticated-orcid":false,"given":"Carolyn E.","family":"Beck","sequence":"additional","affiliation":[{"name":"9Division of Paediatric Medicine, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4668-5124","authenticated-orcid":false,"given":"Justin W.","family":"Yan","sequence":"additional","affiliation":[{"name":"10Lawson Health Research Institute, London Health Sciences Centre, Western University, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Porter","sequence":"additional","affiliation":[{"name":"11Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH"},{"name":"12Division of Emergency Medicine, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Kang","sequence":"additional","affiliation":[{"name":"13Joseph Brant Hospital, Burlington, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1689-3344","authenticated-orcid":false,"given":"Kathryn E.","family":"Webert","sequence":"additional","affiliation":[{"name":"14Canadian Blood Services, Ancaster, ON, Canada"},{"name":"15Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8122-0077","authenticated-orcid":false,"given":"Clare","family":"O'Connor","sequence":"additional","affiliation":[{"name":"16Quality, Patient Safety and Patient Relations, St. Joseph\u2019s Healthcare Hamilton, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pruitt","sequence":"additional","affiliation":[{"name":"17Platelet Disorder Support Association, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7033-1647","authenticated-orcid":false,"given":"Jennifer","family":"MacWhirter-DiRaimo","sequence":"additional","affiliation":[{"name":"17Platelet Disorder Support Association, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Paynter","sequence":"additional","affiliation":[{"name":"17Platelet Disorder Support Association, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Strachan","sequence":"additional","affiliation":[{"name":"17Platelet Disorder Support Association, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"St John","sequence":"additional","affiliation":[{"name":"1Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Molnar","sequence":"additional","affiliation":[{"name":"1Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0943-8853","authenticated-orcid":false,"given":"Donald M.","family":"Arnold","sequence":"additional","affiliation":[{"name":"1Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada"},{"name":"3Department of Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"issue":"8","key":"2026082510521247500_bib1","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/jth.15368","article-title":"Definition of a critical bleed in patients with immune thrombocytopenia: communication from the ISTH SSC Subcommittee on Platelet Immunology","volume":"19","author":"Sirotich","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2026082510521247500_bib2","doi-asserted-by":"crossref","first-page":"i2089","DOI":"10.1136\/bmj.i2089","article-title":"GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: clinical practice guidelines","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"2026082510521247500_bib3","doi-asserted-by":"crossref","first-page":"i2016","DOI":"10.1136\/bmj.i2016","article-title":"GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: introduction","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"issue":"7","key":"2026082510521247500_bib4","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","article-title":"GRADE guidelines: 15. Going from evidence to recommendation - determinants of a recommendation\u2019s direction and strength","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"2026082510521247500_bib5","doi-asserted-by":"crossref","first-page":"e081903","DOI":"10.1136\/bmj-2024-081903","article-title":"Core GRADE 1: overview of the core GRADE approach","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"key":"2026082510521247500_bib6","doi-asserted-by":"crossref","first-page":"e083867","DOI":"10.1136\/bmj-2024-083867","article-title":"Core GRADE 7: principles for moving from evidence to recommendations and decisions","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"issue":"3","key":"2026082510521247500_bib7","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1503\/cmaj.131237","article-title":"Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise","volume":"186","author":"Sch\u00fcnemann","year":"2014","journal-title":"CMAJ Canadian Med Assoc J"},{"key":"2026082510521247500_bib8","volume-title":"Clinical Practice Guidelines We Can Trust","year":"2011"},{"issue":"7","key":"2026082510521247500_bib9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-156-7-201204030-00009","article-title":"Guidelines International Network: toward international standards for clinical practice guidelines","volume":"156","author":"Qaseem","year":"2012","journal-title":"Ann Intern Med"},{"issue":"7","key":"2026082510521247500_bib10","doi-asserted-by":"crossref","first-page":"548","DOI":"10.7326\/M14-1885","article-title":"Guidelines International Network: principles for disclosure of interests and management of conflicts in guidelines","volume":"163","author":"Sch\u00fcnemann","year":"2015","journal-title":"Ann Intern Med"},{"issue":"16","key":"2026082510521247500_bib11","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2026082510521247500_bib12","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/j.1538-7836.2006.02147.x","article-title":"Prevalence of immune thrombocytopenia: analyses of administrative data","volume":"4","author":"Segal","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2026082510521247500_bib13","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1055\/a-2508-1112","article-title":"Primary versus secondary immune thrombocytopenia (ITP): a meeting report from the 2023 McMaster ITP Summit","volume":"125","author":"Modi","year":"2025","journal-title":"Thromb Haemost"},{"issue":"11","key":"2026082510521247500_bib14","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1001\/archinte.160.11.1630","article-title":"The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts","volume":"160","author":"Cohen","year":"2000","journal-title":"Arch Intern Med"},{"issue":"3","key":"2026082510521247500_bib15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/jth.12813","article-title":"Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review","volume":"13","author":"Neunert","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2026082510521247500_bib16","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3109\/09537104.2016.1143923","article-title":"Hospitalizations in pediatric patients with immune thrombocytopenia in the United States","volume":"27","author":"Tarantino","year":"2016","journal-title":"Platelets"},{"issue":"10","key":"2026082510521247500_bib17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/ajh.21500","article-title":"Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura","volume":"84","author":"Danese","year":"2009","journal-title":"Am J Hematol"},{"issue":"23","key":"2026082510521247500_bib18","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1182\/blood-2009-04-215525","article-title":"Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases","volume":"114","author":"Psaila","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2026082510521247500_bib19","first-page":"e9427","article-title":"Temporal trends of intracranial hemorrhage among immune thrombocytopenia hospitalizations in the United States","volume":"12","author":"Bhatt","year":"2020","journal-title":"Cureus"},{"issue":"22","key":"2026082510521247500_bib20","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"2026082510521247500_bib21","doi-asserted-by":"crossref","first-page":"100822","DOI":"10.1016\/j.blre.2021.100822","article-title":"Immune thrombocytopenia: a review of upfront treatment strategies","volume":"49","author":"Kochhar","year":"2021","journal-title":"Blood Rev"},{"issue":"23","key":"2026082510521247500_bib22","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"2026082510521247500_bib23","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/ejh.14351","article-title":"Treatment of critical bleeds in patients with immune thrombocytopenia: a systematic review","volume":"114","author":"Chowdhury","year":"2025","journal-title":"Eur J Haematol"},{"key":"2026082510521247500_bib24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13643-023-02436-6","article-title":"Treatment of critical bleeding events in patients with immune thrombocytopenia: a protocol for a systematic review and meta-analysis","volume":"13","author":"Sirotich","year":"2024","journal-title":"Syst Rev"},{"issue":"13","key":"2026082510521247500_bib25","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1182\/bloodadvances.2024015494","article-title":"Critical bleeding in adults and children with immune thrombocytopenia: a multicenter cohort study","volume":"9","author":"Sirotich","year":"2025","journal-title":"Blood Adv"},{"key":"2026082510521247500_bib26","author":"Bernard","year":"2009"},{"issue":"7","key":"2026082510521247500_bib27","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/jth.14809","article-title":"Management of major bleeds in patients with immune thrombocytopenia","volume":"18","author":"Mithoowani","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2026082510521247500_bib28","doi-asserted-by":"crossref","first-page":"101777","DOI":"10.1016\/j.eclinm.2022.101777","article-title":"Efficacy and safety of treatments in newly diagnosed adult primary immune thrombocytopenia: a systematic review and network meta-analysis","volume":"56","author":"Wang","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026082510521247500_bib29","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2026082510521247500_bib30","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"7650","key":"2026082510521247500_bib31","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2026082510521247500_bib32","doi-asserted-by":"crossref","first-page":"e081902","DOI":"10.1136\/bmj-2024-081902","article-title":"Why Core GRADE is needed: introduction to a new series in the BMJ","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"issue":"3","key":"2026082510521247500_bib33","doi-asserted-by":"crossref","first-page":"427","DOI":"10.55519\/JAMC-03-9786","article-title":"Comparison of efficacy of high dose dexamethasone with conventional prednisolone in the treatment of newly diagnosed adult patients of immunthrombocytopenic purpura","volume":"34","author":"Butt","year":"2022","journal-title":"J Ayub Med Coll Abbottabad"},{"issue":"1","key":"2026082510521247500_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2008-2231-20-7","article-title":"Single course of high dose dexamethasone is more effective than conventional prednisolone therapy in the treatment of primary newly diagnosed immune thrombocytopenia","volume":"20","author":"Mashhadi","year":"2012","journal-title":"Daru"},{"key":"2026082510521247500_bib35","first-page":"1","article-title":"High dose dexamethasone vs prednisolone therapy in newly diagnosed Myanmar adult patients with primary immune thrombocytopenia","volume":"3","author":"Nyein","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"2026082510521247500_bib36","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2015-07-659656","article-title":"High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial","volume":"127","author":"Wei","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2026082510521247500_bib38","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1055\/s-0037-1604168","article-title":"Efficacy of dexamethasone for acute primary immune thrombocytopenia compared to prednisolone: a systematic review and meta-analysis","volume":"1","author":"Arai","year":"2017","journal-title":"TH Open"},{"issue":"6","key":"2026082510521247500_bib39","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1538-7836.2009.03359.x","article-title":"Faster platelet recovery by high-dose dexamethasone compared with standard-dose prednisolone in adult immune thrombocytopenia: a prospective randomized trial","volume":"7","author":"Praituan","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2026082510521247500_bib40","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1046\/j.1365-2141.1998.01096.x","article-title":"Efficacy of high-dose methylprednisolone as a first-line therapy in adult patients with idiopathic thrombocytopenic purpura","volume":"103","author":"Alpdo\u01e7an","year":"1998","journal-title":"Br J Haematol"},{"key":"2026082510521247500_bib41","author":"Yasir","year":"2023"},{"issue":"9300","key":"2026082510521247500_bib42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(02)07275-6","article-title":"Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial","volume":"359","author":"Godeau","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"2026082510521247500_bib43","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood.V82.5.1415.bloodjournal8251415","article-title":"Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin","volume":"82","author":"Godeau","year":"1993","journal-title":"Blood"},{"key":"2026082510521247500_bib44","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/bjh.17692","article-title":"A single 1 g\/kg dose of intravenous immunoglobulin is a safe and effective treatment for immune thrombocytopenia; results of the first HaemSTAR \u201cFlash-Mob\u201d retrospective study incorporating 961 patients","volume":"196","author":"Nicolson","year":"2022","journal-title":"Br J Haematol"},{"issue":"13","key":"2026082510521247500_bib45","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1001\/jama.1983.03330370058033","article-title":"High-dose intravenous immunoglobulin therapy in patients with immune thrombocytopenic purpura","volume":"249","author":"Carroll","year":"1983","journal-title":"JAMA"},{"issue":"2","key":"2026082510521247500_bib46","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood.V62.2.480.480","article-title":"Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura","volume":"62","author":"Bussel","year":"1983","journal-title":"Blood"},{"issue":"8316","key":"2026082510521247500_bib47","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0140-6736(83)91738-5","article-title":"High-dose intravenous IgG in adults with autoimmune thrombocytopenia","volume":"1","author":"Newland","year":"1983","journal-title":"Lancet"},{"issue":"4","key":"2026082510521247500_bib48","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1365-2141.1999.01766.x","article-title":"Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g\/kg b.w","volume":"107","author":"Godeau","year":"1999","journal-title":"Br J Haematol"},{"issue":"5","key":"2026082510521247500_bib49","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-3148.2009.00945.x","article-title":"Clinical efficacy and safety of Flebogammadif\u00ae, a new high-purity human intravenous immunoglobulin, in adult patients with chronic idiopathic thrombocytopenic purpura","volume":"19","author":"Julia","year":"2009","journal-title":"Transfus Med"},{"issue":"3","key":"2026082510521247500_bib50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.14740\/jh385w","article-title":"Efficacy and safety of IQYMUNE\u00ae, a ten percent intravenous immunoglobulin in adult patients with chronic, primary immune thrombocytopenia","volume":"7","author":"Rodeghiero","year":"2018","journal-title":"J Hematol"},{"issue":"1","key":"2026082510521247500_bib51","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/tme.12573","article-title":"Efficacy and safety of a new intravenous immunoglobulin Panzyga\u00ae in chronic immune thrombocytopenia","volume":"29","author":"Arbach","year":"2019","journal-title":"Transfus Med"},{"issue":"5","key":"2026082510521247500_bib52","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1179\/102453310X12719010991867","article-title":"Efficacy and safety of a new intravenous immunoglobulin 10% formulation octagam\u00ae 10% in patients with immune thrombocytopenia","volume":"15","author":"Robak","year":"2010","journal-title":"Hematology"},{"issue":"4","key":"2026082510521247500_bib53","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1179\/102453309X439773","article-title":"Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura","volume":"14","author":"Robak","year":"2009","journal-title":"Hematology"},{"issue":"21","key":"2026082510521247500_bib54","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1056\/NEJM198205273062102","article-title":"Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin","volume":"306","author":"Fehr","year":"1982","journal-title":"N Engl J Med"},{"issue":"6","key":"2026082510521247500_bib55","doi-asserted-by":"crossref","first-page":"808","DOI":"10.7326\/0003-4819-104-6-808","article-title":"Urgent treatment of idiopathic thrombocytopenic purpura with single-dose gammaglobulin infusion followed by platelet transfusion","volume":"104","author":"Baumann","year":"1986","journal-title":"Ann Intern Med"},{"issue":"1","key":"2026082510521247500_bib56","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10238-025-01658-3","article-title":"Efficacy and safety of a new 10% intravenous immunoglobulin (IVIG) in Chinese patients with primary immune thrombocytopenia (ITP): a multicenter, single-arm, phase III trial","volume":"25","author":"Cai","year":"2025","journal-title":"Clin Exp Med"},{"issue":"2","key":"2026082510521247500_bib57","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2217\/imt-2018-0165","article-title":"Safety and efficacy of intravenous immunoglobulin Flebogamma\u00ae 10% DIF in patients with immune thrombocytopenic purpura","volume":"11","author":"Apte","year":"2019","journal-title":"Immunotherapy"},{"issue":"12","key":"2026082510521247500_bib58","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2217\/imt-2016-0088","article-title":"Safety and efficacy of a 10% intravenous immunoglobulin preparation in patients with immune thrombocytopenic purpura: results of two international, multicenter studies","volume":"8","author":"Kovaleva","year":"2016","journal-title":"Immunotherapy"},{"issue":"3","key":"2026082510521247500_bib59","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jama.2013.15267","article-title":"FDA: thrombosis risk with immune globulin products","volume":"310","author":"Mitka","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"2026082510521247500_bib60","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jaip.2013.09.012","article-title":"Adverse effects of IgG therapy","volume":"1","author":"Berger","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"2026082510521247500_bib61","first-page":"60","article-title":"Important drug warning: immune globulin intravenous (human) (IGIV) products","volume":"19","author":"Epstein","year":"2000","journal-title":"Neonatal Netw"},{"issue":"8924","key":"2026082510521247500_bib62","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0140-6736(94)92205-5","article-title":"Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura","volume":"344","author":"Blanchette","year":"1994","journal-title":"Lancet"},{"issue":"4","key":"2026082510521247500_bib63","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jpeds.2005.11.019","article-title":"Single dose of anti-D immune globulin at 75 micro\/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children","volume":"148","author":"Tarantino","year":"2006","journal-title":"J Pediatr"},{"issue":"4","key":"2026082510521247500_bib64","first-page":"295","article-title":"A randomized and comparative study of intravenous immunoglobulin and mega dose methylprednisolone treatments in children with acute idiopathic thrombocytopenic purpura","volume":"45","author":"Erduran","year":"2003","journal-title":"Turk J Pediatr"},{"issue":"1","key":"2026082510521247500_bib65","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/trf.15069","article-title":"Platelet transfusion practices in immune thrombocytopenia related hospitalizations","volume":"59","author":"Goel","year":"2019","journal-title":"Transfusion (Paris)"},{"issue":"3","key":"2026082510521247500_bib66","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bjh.14423","article-title":"Guidelines for the use of platelet transfusions","volume":"176","author":"Estcourt","year":"2017","journal-title":"Br J Haematol"},{"issue":"6","key":"2026082510521247500_bib67","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0002-9343(86)90664-9","article-title":"Efficacy of platelet transfusions in immune thrombocytopenia","volume":"80","author":"Carr","year":"1986","journal-title":"Am J Med"},{"issue":"2","key":"2026082510521247500_bib68","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ajh.21060","article-title":"Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients","volume":"83","author":"Spahr","year":"2008","journal-title":"Am J Hematol"},{"issue":"5","key":"2026082510521247500_bib69","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1160\/TH08-06-0418","article-title":"Massive platelet transfusion is a rapidly effective emergency treatment in patients with refractory autoimmune thrombocytopenia","volume":"100","author":"Salama","year":"2008","journal-title":"Thromb Haemost"},{"key":"2026082510521247500_bib70","author":"Agarwal","year":"2024"},{"key":"2026082510521247500_bib71","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(17)30638-4","article-title":"Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial","volume":"389","author":"Shakur","year":"2017","journal-title":"Lancet"},{"key":"2026082510521247500_bib72","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(10)60835-5","article-title":"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial","volume":"376","author":"Olldashi","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"2026082510521247500_bib73","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3171\/jns.2002.97.4.0771","article-title":"Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study","volume":"97","author":"Hillman","year":"2002","journal-title":"J Neurosurg"},{"issue":"2","key":"2026082510521247500_bib74","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/ejh.13348","article-title":"The many roles of tranexamic acid: an overview of the clinical indications for TXA in medical and surgical patients","volume":"104","author":"Cai","year":"2020","journal-title":"Eur J Haematol"},{"issue":"8","key":"2026082510521247500_bib75","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/vox.12549","article-title":"Successful treatment of bleeding with tranexamic acid in a series of 12 patients with immune thrombocytopenia","volume":"112","author":"Mayer","year":"2017","journal-title":"Vox Sang"},{"issue":"9","key":"2026082510521247500_bib76","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1001\/archinte.1989.00390090039008","article-title":"Control of bleeding in patients with immune and nonimmune thrombocytopenia with aminocaproic acid","volume":"149","author":"Bartholomew","year":"1989","journal-title":"Arch Intern Med"},{"issue":"1","key":"2026082510521247500_bib77","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jama.1980.03300270023023","article-title":"Aminocaproic acid: use in control of hemorrhage in patients with amegakaryocytic thrombocytopenia","volume":"243","author":"Gardner","year":"1980","journal-title":"JAMA"},{"key":"2026082510521247500_bib78","author":"Chauncey","year":"2025"},{"issue":"1","key":"2026082510521247500_bib79","doi-asserted-by":"crossref","first-page":"e247334","DOI":"10.1136\/bcr-2021-247334","article-title":"Tranexamic acid-induced ureteric clot obstruction in a patient with urothelial cell carcinoma resulting in upper urinary tract perforation","volume":"15","author":"Maresca","year":"2022","journal-title":"BMJ Case Rep"},{"issue":"4","key":"2026082510521247500_bib80","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000381657","article-title":"Romiplostim treatment in adults with immune thrombocytopenia of varying duration and severity","volume":"134","author":"Janssens","year":"2015","journal-title":"Acta Haematol"},{"issue":"1","key":"2026082510521247500_bib81","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12185-011-0886-8","article-title":"Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized phase III clinical trial","volume":"94","author":"Shirasugi","year":"2011","journal-title":"Int J Hematol"},{"key":"2026082510521247500_bib82","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"Jurczak","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"2026082510521247500_bib83","first-page":"32","article-title":"The efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia [in Chinese]","volume":"39","author":"Huang","year":"2018","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"23","key":"2026082510521247500_bib84","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"issue":"25","key":"2026082510521247500_bib85","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1182\/blood-2013-07-514398","article-title":"A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia","volume":"123","author":"Bussel","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2026082510521247500_bib86","first-page":"202","article-title":"A clinical analysis of treatment with recombinant human thrombopoietin combined with large doses of dexamethasone in primary immune thrombocytopenia","volume":"55","author":"Sun","year":"2016","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"2026082510521247500_bib87","first-page":"883","article-title":"[A clinical comparative study on treatment of severe newly diagnosed immune thrombocytopenia by recombinant human thrombopoietin combined with glucocorticoid]","volume":"34","author":"Gu","year":"2013","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"2","key":"2026082510521247500_bib88","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000452992","article-title":"A 2-year, longitudinal, prospective study of the effects of eltrombopag on bone marrow in patients with chronic immune thrombocytopenia","volume":"137","author":"Brynes","year":"2017","journal-title":"Acta Haematol"},{"issue":"7","key":"2026082510521247500_bib89","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s00277-016-2682-2","article-title":"Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia","volume":"95","author":"Janssens","year":"2016","journal-title":"Ann Hematol"},{"issue":"3","key":"2026082510521247500_bib90","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/bjh.15803","article-title":"Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies","volume":"185","author":"Kuter","year":"2019","journal-title":"Br J Haematol"},{"issue":"13","key":"2026082510521247500_bib91","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1182\/blood-2004-06-2223","article-title":"The use of recombinant factor VIIa in the treatment of bleeding disorders","volume":"104","author":"Roberts","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2026082510521247500_bib92","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1309\/D0G0C96V05CJ5B4J","article-title":"Recombinant factor VIIa in the treatment of bleeding","volume":"121","author":"Midathada","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"2026082510521247500_bib93","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/bja\/aew276","article-title":"Reduced mortality by meeting guideline criteria before using recombinant activated factor VII in severe trauma patients with massive bleeding","volume":"117","author":"Payen","year":"2016","journal-title":"Br J Anaesth"},{"issue":"1","key":"2026082510521247500_bib94","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00277-008-0608-3","article-title":"Experiences with recombinant FVIIa in the emergency treatment of patients with autoimmune thrombocytopenia: a review of the literature","volume":"88","author":"Salama","year":"2009","journal-title":"Ann Hematol"},{"key":"2026082510521247500_bib95","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2147\/JBM.S219573","article-title":"Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC)","volume":"10","author":"Rajpurkar","year":"2019","journal-title":"J Blood Med"},{"issue":"19","key":"2026082510521247500_bib96","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1006221","article-title":"Safety of recombinant activated factor VII in randomized clinical trials","volume":"363","author":"Levi","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"2026082510521247500_bib97","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1308\/003588414X13814021677593","article-title":"Splenectomy results from an 18-year single centre experience","volume":"96","author":"Davies","year":"2014","journal-title":"Ann R Coll Surg Engl"},{"issue":"9","key":"2026082510521247500_bib98","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1182\/blood-2004-03-1168","article-title":"Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications","volume":"104","author":"Kojouri","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2026082510521247500_bib99","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00277-002-0461-8","article-title":"Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses","volume":"81","author":"Kumar","year":"2002","journal-title":"Ann Hematol"},{"issue":"8","key":"2026082510521247500_bib100","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.jpedsurg.2012.02.013","article-title":"An analysis of outcomes and treatment costs for children undergoing splenectomy for chronic immune thrombocytopenia purpura","volume":"47","author":"Gwilliam","year":"2012","journal-title":"J Pediatr Surg"},{"issue":"6","key":"2026082510521247500_bib101","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3324\/haematol.2012.075648","article-title":"Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years","volume":"98","author":"Vianelli","year":"2013","journal-title":"Haematologica"},{"issue":"2","key":"2026082510521247500_bib102","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/j.jss.2011.06.031","article-title":"Laparoscopic splenectomy for patients with immune thrombocytopenia and very low platelet count: is platelet transfusion necessary?","volume":"170","author":"Chen","year":"2011","journal-title":"J Surg Res"},{"issue":"1","key":"2026082510521247500_bib103","first-page":"72","article-title":"Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases","volume":"90","author":"Vianelli","year":"2005","journal-title":"Haematologica"},{"issue":"8","key":"2026082510521247500_bib104","doi-asserted-by":"crossref","first-page":"546","DOI":"10.7326\/0003-4819-151-8-200910200-00008","article-title":"Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study","volume":"151","author":"Thomsen","year":"2009","journal-title":"Ann Intern Med"},{"issue":"11","key":"2026082510521247500_bib105","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood-2017-09-742353","article-title":"Splenectomy for immune thrombocytopenia: down but not out","volume":"131","author":"Chaturvedi","year":"2018","journal-title":"Blood"},{"issue":"23","key":"2026082510521247500_bib106","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1182\/blood-2012-12-467068","article-title":"Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia","volume":"121","author":"Boyle","year":"2013","journal-title":"Blood"},{"issue":"48","key":"2026082510521247500_bib107","doi-asserted-by":"crossref","first-page":"e5098","DOI":"10.1097\/MD.0000000000005098","article-title":"Long-term complications of splenectomy in adult immune thrombocytopenia","volume":"95","author":"Thai","year":"2016","journal-title":"Medicine"},{"issue":"6","key":"2026082510521247500_bib108","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0022-3476(05)80400-7","article-title":"A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura","volume":"123","author":"Blanchette","year":"1993","journal-title":"J Pediatr"},{"issue":"4","key":"2026082510521247500_bib109","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00043426-198424000-00001","article-title":"Prednisone therapy for children with newly diagnosed idiopathic thrombocytopenic purpura. A randomized clinical trial","volume":"6","author":"Buchanan","year":"1984","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"3","key":"2026082510521247500_bib110","first-page":"376","article-title":"A prospective, randomized trial of conventional, dose-accelerated corticosteroids and intravenous immunoglobulin in children with newly diagnosed idiopathic thrombocytopenic purpura","volume":"72","author":"Fujisawa","year":"2000","journal-title":"Int J Hematol"},{"issue":"4","key":"2026082510521247500_bib111","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/08880010252899370","article-title":"Clinical course of children with immune thrombocytopenic purpura treated with intravenous immunoglobulin G or megadose methylprednisolone or observed without therapy","volume":"19","author":"Duru","year":"2002","journal-title":"Pediatr Hematol Oncol"},{"issue":"6","key":"2026082510521247500_bib112","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s12185-020-02977-9","article-title":"High-dose dexamethasone as a replacement for traditional prednisone as the first-line treatment in children with previously untreated primary immune thrombocytopenia: a prospective, randomized single-center study","volume":"112","author":"Ma","year":"2020","journal-title":"Int J Hematol"},{"issue":"10","key":"2026082510521247500_bib138","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2352-3026(16)30109-0","article-title":"High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"3","author":"Mithoowani","year":"2016","journal-title":"Lancet Haematol"},{"issue":"9","key":"2026082510521247500_bib113","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2018-02-830844","article-title":"Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial","volume":"132","author":"Heitink-Poll\u00e9","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2026082510521247500_bib114","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/00043426-200210000-00008","article-title":"Randomized trial of high-dose methylprednisolone versus intravenous immunoglobulin for the treatment of acute idiopathic thrombocytopenic purpura in children","volume":"24","author":"Ancona","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"2026082510521247500_bib115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s11239-012-0801-z","article-title":"Comparison of anti-D immunoglobulin, methylprednisolone, or intravenous immunoglobulin therapy in newly diagnosed pediatric immune thrombocytopenic purpura","volume":"35","author":"Celik","year":"2013","journal-title":"J Thromb Thrombolysis"},{"issue":"8","key":"2026082510521247500_bib116","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1651-2227.1996.tb14183.x","article-title":"Randomized trial comparing intravenous immunoglobulin with methylprednisolone pulse therapy in acute idiopathic thrombocytopenic purpura. Danish I.T.P. Study Group","volume":"85","author":"Rosth\u00f8j","year":"1996","journal-title":"Acta Paediatr"},{"key":"2026082510521247500_bib117","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jpeds.2018.07.065","article-title":"Efficacy and safety of anti-D immunoglobulins versus intravenous immunoglobulins for immune thrombocytopenia in children: systematic review and meta-analysis of randomized controlled trials","volume":"204","author":"Lioger","year":"2019","journal-title":"J Pediatr"},{"key":"2026082510521247500_bib118","unstructured":"KAMADA\n          . WinRho SDF for the Treatment of Immune Thrombocytopenic Purpura (ITP). Accessed 14 April 2025. https:\/\/winrho.com\/."},{"issue":"3","key":"2026082510521247500_bib119","first-page":"421","article-title":"Tranexamic acid in a case report of life-threatening nontraumatic hemorrhage in immune thrombocytopenic purpura","volume":"4","author":"Randall","year":"2020","journal-title":"Clin Pract Cases Emerg Med"},{"issue":"10039","key":"2026082510521247500_bib120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0140-6736(16)00279-8","article-title":"Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"Tarantino","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"2026082510521247500_bib121","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2010-10-313908","article-title":"A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia","volume":"118","author":"Bussel","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2026082510521247500_bib122","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00277-011-1172-9","article-title":"Romiplostim in children with chronic refractory ITP: randomized placebo controlled study","volume":"90","author":"Elalfy","year":"2011","journal-title":"Ann Hematol"},{"issue":"10004","key":"2026082510521247500_bib123","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(15)61107-2","article-title":"Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial","volume":"386","author":"Grainger","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"2026082510521247500_bib124","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S2352-3026(15)00114-3","article-title":"Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study","volume":"2","author":"Bussel","year":"2015","journal-title":"Lancet Haematol"},{"issue":"7","key":"2026082510521247500_bib125","doi-asserted-by":"crossref","first-page":"e494","DOI":"10.1016\/S2352-3026(25)00107-3","article-title":"Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study","volume":"12","author":"Grace","year":"2025","journal-title":"Lancet Haematol"},{"issue":"3","key":"2026082510521247500_bib126","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/ejh.12586","article-title":"Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients","volume":"96","author":"Stirnemann","year":"2016","journal-title":"Eur J Haematol"},{"issue":"10","key":"2026082510521247500_bib127","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1182\/blood-2007-01-065763","article-title":"Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP)","volume":"110","author":"Boruchov","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2026082510521247500_bib128","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12185-015-1903-0","article-title":"Clinical efficacy and tolerability of vincristine in splenectomized patients with refractory or relapsed immune thrombocytopenia: a retrospective single-center study","volume":"103","author":"Park","year":"2016","journal-title":"Int J Hematol"},{"issue":"2","key":"2026082510521247500_bib129","doi-asserted-by":"crossref","first-page":"192","DOI":"10.7326\/0003-4819-100-2-192","article-title":"Slow infusion of vinca alkaloids in the treatment of idiopathic thrombocytopenic purpura","volume":"100","author":"Ahn","year":"1984","journal-title":"Ann Intern Med"},{"issue":"8","key":"2026082510521247500_bib130","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1056\/NEJM197408222910802","article-title":"Vincristine therapy of idiopathic and secondary thrombocytopenias","volume":"291","author":"Ahn","year":"1974","journal-title":"N Engl J Med"},{"issue":"3","key":"2026082510521247500_bib131","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1365-2141.1994.tb04810.x","article-title":"A randomized trial comparing vinblastine in slow infusion and by bolus i.v. injection in idiopathic thrombocytopenic purpura: a report on 42 patients","volume":"86","author":"Facon","year":"1994","journal-title":"Br J Haematol"},{"issue":"4","key":"2026082510521247500_bib132","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/BF01728791","article-title":"Slow infusions of vinblastine in the treatment of adult idiopathic thrombocytopenic purpura: a report on 43 cases","volume":"60","author":"Fenaux","year":"1990","journal-title":"Blut"},{"issue":"9","key":"2026082510521247500_bib133","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/ajh.22081","article-title":"Vinblastine in the treatment of children and adolescents with refractory immune thrombocytopenia","volume":"86","author":"Fresneau","year":"2011","journal-title":"Am J Hematol"},{"issue":"6","key":"2026082510521247500_bib134","doi-asserted-by":"crossref","first-page":"597","DOI":"10.4065\/71.6.597","article-title":"Role of plasmapheresis in thrombocytopenic purpura associated with waldenstr\u00f6m\u2019s macroglobulinemia","volume":"71","author":"Patel","year":"1996","journal-title":"Mayo Clin Proc"},{"key":"2026082510521247500_bib135","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1046\/j.1537-2995.1984.24585017826.x","article-title":"Intensive plasma exchange therapy in ten patients with idiopathic thrombocytopenic purpura","volume":"24","author":"Hogan","year":"1984","journal-title":"Transfusion (Paris)"},{"key":"2026082510521247500_bib136","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1046\/j.1537-2995.1988.28188127949.x","article-title":"Combined plasma exchange and intravenous gammaglobulin in the treatment of patients with refractory immune thrombocytopenic purpura","volume":"28","author":"Saal","year":"1988","journal-title":"Transfusion (Paris)"},{"issue":"10","key":"2026082510521247500_bib137","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.revmed.2005.06.009","article-title":"\u00c9changes plasmatiques dans les formes graves de purpura thrombop\u00e9nique immunologique aigu","volume":"26","author":"Masseau","year":"2005","journal-title":"Rev Med Interne"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/16\/5558\/2537688\/blooda_adv-2025-018818-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/16\/5558\/2537688\/blooda_adv-2025-018818-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:56:26Z","timestamp":1787669786000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/16\/5558\/566423\/Guideline-on-the-emergency-management-of-critical"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":137,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,8,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018818","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,25]]},"published":{"date-parts":[[2026,8,13]]}}}